GRAM domain containing 1AGenealiases: KIAA1533 · LAMa
Q-omics provides the consensus-scored GRAMD1A profile across patient tissues and cancer cell-line models. GRAMD1A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GRAMD1A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, GRAMD1A RNA expression shows 18,336 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and KIRC as cancer lineages where GRAMD1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRAMD1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRAMD1A survival associations across molecular data types. GRAMD1A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRAMD1A RNA expression–survival associations across cancer types. High GRAMD1A expression shows unfavorable associations in KIRP, LIHC, KIRC, LGG, MESO and OV. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GRAMD1A RNA expression.
This table summarizes GRAMD1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GRAMD1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRAMD1A shows higher tumor expression in KIRC, KIRP, HNSC, COAD, LIHC and THCA. The KIRC box plot shows higher GRAMD1A RNA expression in tumor versus normal tissue (log2 FC = +1.455, t-test p < 0.001).
This table shows molecular features associated with GRAMD1A in patient tissues and cancer cell lines. In patient samples, GRAMD1A shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, GRAMD1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
